Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8602, Japan, kawada@nms.ac.jp.
T
T
Kawada
D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000503:physiopathology*; D019379:Teriparatide / Q000494:pharmacology*
D050071:Bone Density Conservation Agents; D019379:Teriparatide